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Introduction: Hypertension is a common complication during pregnancy, affecting 10% of pregnant women
worldwide. Several microRNA (miRNA) were shown to be involved in hypertensive disorders of pregnancy. In
preeclampsia (PE), placental dysfunction causes the enhanced release of extracellular vesicle-derived miRNAs.
The hypoxia-sensitive hsa-mir-210 is the most common PE-associated miRNA, but its exosomal profile has not
been investigated.
Objectives: Our aims were to measure exosomal total-miRNA concentration and to perform expression analysis
of circulating exosomal hsa-miR-210 in women affected by chronic hypertension (CHT) gestational hypertension
(GHT) or PE.
Materials and methods: We collected plasma samples from women with CHT, GHT, PE (moderate: mPE and se-
vere: sPE) and from normotensive pregnancies. Exosomal miRNAs were extracted and miRNA concentration was
measured. RT-PCR was carried out with hsa-miR-210-3p-specific primers and relative expression was calculated
using the comparative Ct method.
Results: The total-miRNA concentration was different in the disease subgroups, and was significantly higher
in mPE and sPE compared to the other groups. We found a significant difference in the relative exosomal
hsa-miR-210-3p expression between all hypertensive groups compared to the normotensive samples, but sig-
nificant upregulation was only observed in case of mPE and sPE patients. Both the level of total-miRNA and
hsa-miR-210 expression was higher in case of severe PE.
Conclusions: The level of circulating exosomal total-miRNA and hsa-miR-210 was elevated in women with PE,
and it was higher in the severe form. We showed that hsa-miR-210 is secreted via exosomes, which may have a
role in the pathomechanism of the disease.
1. Introduction
1.1. The different forms of pregnancy hypertension
Hypertension is a common complication during pregnancy, affect-
ing up to 10% of pregnant women worldwide. Considering different
types of hypertension in pregnancy, around 1% of pregnancies are af-
fected by chronic hypertension (CHT), 5–6% by gestational or preg-
nancy-induced hypertension (GHT) and 1–2% by preeclampsia (PE) [1].
CHT is defined as blood pressure (BP) exceeding 140/90 mmHg be-
fore pregnancy or prior to 20 weeks of gestation. About 20–25% of
women with CHT develops superimposed preeclampsia (SIPE) during
pregnancy [2]. In GHT, hypertension develops in the latter part of preg-
nancy without any other symptoms of PE and followed by BP normal-
ization postpartum. PE is a multisystem disease, characterized by the
development of hypertension and proteinuria after 20 weeks of gesta-
tion. In the absence of proteinuria, the diagnosis may be established by
the presence of other maternal organ dysfunctions including thrombocy-
topenia, impaired liver functions, renal insufficiency, pulmonary edema
and cerebral or visual disturbances previously not experienced [3]. PE
is one of the leading causes of maternal and fetal/neonatal morbidity
and mortality all around the globe [4]. Stillbirth is twice as common in
PE and more than 30% of cases are accompanied by intrauterine growth
restriction (IUGR) [5].
Although the pathophysiology of the disease is still elusive, it is be-
lieved that PE is a consequence of altered trophoblast invasion and spi
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ral artery remodeling, which hinders maternal blood flow to the pla-
centa and also leads to high perfusion pressure constituting shear stress
to the trophoblast layer [6]. This phenomenon results in injured tro-
phoblast and subsequent release of possibly harmful materials including
cell fragments and extracellular vesicles (EVs) into the maternal circula-
tion [7].
1.2. Extracellular vesicles in pregnancy
EVs are lipid bilayer structures that are released from cells into the
extracellular environment. They incorporate proteins, lipids, non-cod-
ing RNAs, and other regulatory elements. Multiple EV types can be pro-
duced by different cells, including red blood cells [8], fibroblasts [9],
endothelial cells [10], and trophoblasts [11]. After secretion from cells,
EVs may modulate the activity of neighboring cells or travel to distal
regions serving a non-hormonal way of intercellular communication.
EVs are distinguished by size, function, biogenesis, and morphology into
three categories: microvesicles, apoptotic bodies, and exosomes.
In this article, we will only assay exosomes in relation to pregnancy.
Exosomes are the smallest of EVs (40–120 nm) with a density ranging
from 1,13 to 1,19 g/mL [12]. They are characterized by endosomal ori-
gin with formation through the inward budding of multivesicular bodies
and release into extracellular space via exocytosis. Exosomes from dif-
ferent cell types are enriched with endosome-associated proteins (e.g.
CD63, CD89, and TSG101) [13]. Placenta-derived exosomes can be de-
tected using the immunoreactive placental alkaline phosphatase protein
(PLAP) marker. In the course of physiologically normal pregnancy, exo-
somes of trophoblast origin can be detected from the 6⁠th week of gesta-
tion in the maternal circulation. The number of these vesicles increases
until term and returns to non-pregnant levels in 48 h after delivery [14].
The levels of placenta-specific exosomes and their content may serve in-
formation of placental health. In PE, placental dysfunction causes the
enhanced shedding of trophoblast-derived EVs into the maternal circula-
tion and subsequent release of toxic material including anti-angiogenic
factors, pro-inflammatory mediators and microRNAs (miRNAs) [15].
1.3. microRNAs in pregnancy
miRNAs are endogenous, 20–22 nucleotides long, non-coding RNA
molecules, which have a special role in fine-tuning gene expression.
To date, almost 2000 miRNA sequences have been identified in human
[16] and predicted to regulate approximately 30% of all protein-coding
genes [17]. miRNAs control gene expression at the post-transcriptional
level, by either repressing protein translation of target genes or induc-
ing target mRNA degradation. One particular miRNA is able to control
multiple genes, and a single gene can be a target of several miRNAs.
miRNAs are involved mainly in all important biological process, such
as cell proliferation, differentiation, apoptosis, and metabolism, besides
also closely related to the pathogenesis of several human diseases [18].
More than one thousand miRNAs are expressed by different layers of
the human placenta, some of which are primate-specific and only pre-
sent in placental and stem cells [19]. The function of placentally ex-
pressed miRNAs is not fully elucidated but is clear that they take part
in the regulation of placental development and are essential for normal
physiology [20]. Differently expressed miRNAs, both placenta-specific
and not placenta-specific, were reported in pregnancy-related hyperten-
sive disorders [21–23].miRNAs are released from trophoblast cells to
maternal circulation mainly via the exosomal pathway, but secretion
in other forms are described as well, like microvesicles, apoptotic bod-
ies, and protein-bound miRNAs [24]. In either way, extracellular miR-
NAs have been shown to be stable and protected from RNase degra-
dation, which implicates their use as potential biomarkers [25]. The
miRNA profile in exosomes and their donor cells hardly correlate, sug-
gesting specific direct sorting of miRNA [26]. Exosomal miRNAs can be
transferred to recipient cells, where they mediate functional effects by
altering gene expression [27].
Altered placental development and spiral artery remodeling leads
to placental hypoxia, which can change the number and content of se-
creted EVs. It has been shown that under hypoxic conditions trophoblast
cells release harmful agents into the maternal blood flow, which may
induce drastic biological changes systemically [28,29].
1.4. Hypoxia-responsive miRNAs and hypertension in pregnancy
miR-210 is one of the so-called “hypoxamiRs”, which are sensitive
to the hypoxic environment [30]. It is specifically activated by HIF-1α
[31] and considered as one of the hallmarks of hypoxic responses in
several cell types including trophoblast and endothelial cells. HIF-1α
is directly recruited to the hypoxia-responsive element (HRE) in the
miR-210 promoter, which induces miR-210 transcription [32]. Creating
a positive feed-back loop, miR-210 stabilizes HIF-1α by targeting an en-
zyme which decreases HIF-1α stability [33].
The direct consequences of the elevated levels of miR-210 in preg-
nancy are not clear. Hsa-mir-210-3p is the most common PE-associated
miRNA, as it was found to be overexpressed both in the placenta and in
the circulation of women with PE [23]. Nevertheless, miR-210 has not
been investigated in other forms of pregnancy hypertensions, and the
question whether it acts via the exosome-mediated or other pathways
has not been addressed either. In this study, our aims were to quantify
exosomal total-miRNA concentration and to perform expression analy-
sis of exosomal hsa-miR-210-3p in the circulation of women affected by
CHT, GHT, and PE. In the latter group, we also studied whether these
factors change with the severity of the disease.
2. Materials and methods
2.1. Participants
Study participants had been recruited during routine prenatal care
or following hospital admission between the 24 and 40th weeks of ges-
tation during 2015–2017 at 1st Department of Obstetrics and Gynecol-
ogy, Semmelweis University, Budapest, Hungary. We collected plasma
samples from healthy controls (n = 34) and from pregnant woman af-
fected by different types of hypertension: CHT (n = 16), GHT (n = 14),
PE (n = 34, from which 11 were superimposed and 23 were de novo
PE). The patient characteristics are summarized in Table 1 in the Results
section.
Inclusion criteria for the GHT group were the de novo development
of high blood pressure without any of the abnormalities that define
PE. CHT was defined as BP exceeding 140/90 mmHg before pregnancy
or prior to 20 weeks of gestation. Inclusion criteria for the PE group
were BP greater than 140/90 mmHg with proteinuria >300 mg/24 h
or at least 1 g/L (++) on dipstick testing. As we wanted to conduct
the analysis in the context of severity, PE group was divided to severe
(n = 19) and moderate (n = 15) subgroups. Moderate PE was defined
as BP greater than 140/90 mmHg, and cases in which BP exceeded 160/
110 mmHg or other maternal organ dysfunctions were present includ-
ing thrombocytopenia, impaired liver functions, renal insufficiency, pul-
monary edema and cerebral or visual disturbances, were classified as
severe PE [34]. IUGR was determined by ultrasonography when the es-
timated fetal weight was below the 10th percentile for gestational age
[35].
Pregnancies with ongoing labour, multiple gestations, and congen-
ital malformations were not included. In the normotensive group (N),
exclusion criteria also included the history of pregnancy-related or
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Table 1
Patient characteristics. Maternal age, gestational age, birthweight, and BMI are expressed as median (min-max). Percentage of sample size in each group was noted at IUGR and nulliparity
values.
N CHT GHT mPE sPE
sample size 34 16 14 15 19
maternal age 31,30 (23–38) 33 (25–40) 32,36 (22–41) 30,8 (20–41) 30,42 (15–41)
gestational age at sampling 35,58 (30–39) 32,63 (24–40) 35,71 (25–39) 32,47 (24–37) 31 (24–39)
gestational age at birth 38,94 (36,14–40,86) 37,02 (25–40,86) 37,13 (25,86–39,29) 36,63 (29–40) 31,12 (22,42–38,86)
birthweight 3525,81 (2160–4770) 3118 (1100–4130) 2882 (530–4020) 2648,57 (990–3510) 1555,88 (320–3350)
BMI before pregnancy 26,97 (17,92–32,39) 27,61 (18,42–39,12) 29,02 (20,31–39,51) 28,11 (18,3–35,6) 25,23 (18,96–35,6)
BMI at sampling 26,97 (21,30–35,82) 32,24 (21,97–40,96) 31,97 (23,44–41,47) 33,26 (21,72–42,53) 30,11 (21,56–39,79)
IUGR 0 (0%) 4 (25%) 3 (21,43%) 3 (20%) 7 (36,84%)
nulliparity 10 (29,41%) 6 (37,5%) 2 (14,29%) 8 (53,33%) 11 (57,89%)
other forms of hypertension, spontaneous abortion, preterm birth, and
IUGR.
The study protocol was approved by the Scientific and Research
Ethics Committee of the Medical Research Council (ETT TUKEB) [No:
2379/2014] and written informed consent was obtained from each pa-
tient. The research was conducted in accordance with the Declaration of
Helsinki.
2.2. Sample handling
Venous blood samples were drawn into 4 mL EDTA tubes and kept
at 4 °C until processing. Plasma was separated within few hours by
two-step centrifugation (1. 2500g, 10 min, 4 °C, 2. 12500g, 10 min,
4 °C) and stored in 1.5 ml Eppendorf tubes at −80 °C.
2.3. Exosome and RNA isolation
In the first step, exosomes were isolated from 500 μl plasma us-
ing exosome precipitation solution (Macherey-Nagel GmbH & Co. KG,
Düren, Germany) and resuspended in 300 μl RNase-free water. miR-
NAs were extracted from the diluted exosomes with NucleoSpin miRNA
Plasma Kit (Macherey-Nagel GmbH & Co. KG, Düren, Germany) and dis-
solved in 30 μl RNase-free water. A DNase step was included to remove
traces of genomic DNA due to co-purified DNA might interfere with
qPCR quantification of miRNA.
2.4. Total-miRNA quality and quantity measurement
In order to determine total-miRNA concentration, we applied a
miRNA-specific fluorometric assay using a Qubit® 2.0 Fluorometer
(Thermo Fischer Scientific Inc., Wilmington, USA). The purity of each
sample was checked by Nanodrop spectrophotometer (Thermo Fischer
Scientific Inc., Wilmington, USA) based on the A260/A280 ratio.
2.5. Real-time quantitative PCR
The expression analysis was performed using the miRCURY LNA™
Universal RT microRNA PCR protocol for plasma samples (Exiqon A/
S, Vedbaek, Denmark) according to the manufacturer’s instructions.
Briefly, total-miRNA samples were reverse-transcribed using Universal
cDNA synthesis kit II. UniSp6 RNA spike-in template was added to each
reaction for cDNA synthesis control. cDNA templates were 40× diluted
in nuclease-free water before subsequent amplification.
RT-PCR was carried out using ExiLENT SYBR® Green master mix
with hsa-miR-210-3p specific LNA™ PCR primer set targeting the se-
quence 5′- CUGUGCGUGUGACAGCGGCUGA-3′. The relative expression
was calculated based on the ddCT method and was normalized to
hsa-miR-103a-3p internal control miRNA. Melting curve analysis was
carried out following each PCR run for evaluating the specificity of the
assay.
2.6. Statistics
We used the STATISTICA software package (Statistica, Tulsa, Ok-
lahoma, USA) for statistical analysis. Shapiro-Wilk W test was applied
to assess the normality of the dependent variables. Since nor the to-
tal-miRNA concentration, neither the hsa-miR-210-3p expression fol-
lowed a normal distribution, nonparametric tests were used afterward.
Comparisons among groups were carried out using Kruskal-Wallis
ANOVA integrated with two-tailed Mann-Whitney U test for between
group analysis. Spearman Rank Order correlation was calculated to find
a possible connection between hsa-miR-210 expression and total-miRNA
concentration. miRNA levels were given as median with interquartile
ranges, and fold change values (FC) were calculated when the hyper-
tensive and normotensive groups were compared. FC > 2 and FC < 0,5
was regarded as significant over- and underexpression respectively. A p
value of <0,05 considered as a statistically significant finding.
3. Results
3.1. Total-miRNA concentration
The median value of total-miRNA concentration in exosome samples
varied in the disease subgroups and in the control group as follows: N:
0,26 ng/µl (0,10–0,76 ng/µl); GHT: 0,28 ng/µl (0,16–0,91 ng/µl); CHT:
0,30 ng/µl (0,22–0,38 ng/µl); mPE: 0,83 ng/µl (0,42–1,85 ng/µl); sPE:
1,57 ng/µl (0,25–8,21 ng/µl). The data was represented in box and
whisker plot format in Fig. 1. Overexpression
Fig. 1. Comparison of total-miRNA concentration in different groups by box-plot diagram.
The groups are arranged in ascending order, N: normotensive, CHT: chronic hypertension,
GHT: gestational hypertension, mPE: moderate preeclampsia, sPE: severe preeclampsia. *:
p < 0,5, **: p < 0,01, ***: p < 0,001.
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(FC > 2) was only observed in PE groups, the total-miRNA concen-
tration was three-times higher (FC = 3,19, p < 0,001) in mPE and
six-times higher (FC = 6,03, p < 0,001) in sPE groups than in the
normotensive group. There was significant difference comparing CHT
to mPE (p < 0,05) and sPE (p < 0,001), and GHT to sPE group
(p < 0,01). De novo and superimposed PE could not be segregated
based on the total-miRNA concentration (0,96 (0,25–8,21) vs. 0,57
(0,21–4,00), p > 0,05), and IUGR had no significant impact in the af-
fected groups.
3.2. hsa-miR-210-3p expression
We found significant difference in the relative exosomal
hsa-miR-210-3p expression between the hypertension groups and the
normotensive group (Fig. 2): N: 0,13 (0,10–0,17); CHT: 0,17
(0,13–0,25); GHT: 0,23 (0,17–0,30); mPE: 0,29 (0,20–0,41); sPE: 0,37
(0,26–0,49). The data was represented in box and whisker plot for-
mat in Fig. 2. Overexpression only was observed in mPE (FC = 2,23,
p < 0,001) and in sPE groups (FC = 2,85, p < 0,001) but not in CHT
(FC = 1,31, p < 0,05) and GHT groups (FC = 1,77, p < 0,01) in com-
parison to the control group. There was a significant difference compar-
ing CHT and GHT to sPE group (p < 0,05). De novo and superimposed
PE could not be separated based on the relative hsa-miR-210 expression
(Null,34 (Null,14-Null,73) vs. 0,26 (0,16–0,64), p > 0,05), and IUGR
had no significant impact in the hypertensive groups.
Total-miRNA concentration was positively correlated with
hsa-miR-210 expression in the hypertensive samples (R = 0,41,
p < 0,05) but not in the control samples. This finding was visualized
by scatter plot after log-transformation of the data for graphic purposes
(Fig. 3).
4. Discussion
In this study, our aims were quantity exosomal total-miRNA and to
perform expression analysis of exosomal hsa-miR-210 in the circulation
of pregnant women affected by CHT, GHT, mPE and sPE. The median
value of total-miRNA concentration was different in the disease sub-
groups and was significantly higher in sPE and mPE compared to con-
trol samples. We found a significant difference in the relative exosomal
hsa-miR-210-3p expression between all disease subgroups compared
to normotensive group, however, significant upregulation (FC>2) was
only observed in the circulation of PE patients. Total-miRNA concentra-
tion was positively correlated with hsa-miR-210 expression in the hy-
pertension groups but no correlation was observed in the normoten-
sive group. It may implicate that miR-210 contribution to the total-
Fig. 2. Comparison of relative exosomal hsa-miR-210-3p expression in different groups
by box-plot diagram. The groups are arranged in ascending order, N: normotensive, CHT:
chronic hypertension, GHT: gestational hypertension, mPE: moderate preeclampsia, sPE:
severe preeclampsia. *: p < 0,5, **: p < 0,01, ***: p < 0,001.
Fig. 3. Correlation between total-miRNA concentration and relative hsa-miR-210 expres-
sion in hypertension groups (R = 0,4073, p = 0,002) Log-transformation was performed
on the data for graphic purposes.
miRNA pool was higher in case of hypertension disorders than in nor-
motensive samples.
The role of trophoblast-derived EVs in normal and complicated preg-
nancy could facilitate the improvement of new therapeutic strategies,
including neutralizing harmful EVs and boost the release of ones with
preferential characteristics. Nadkarni et al. showed that recombinant
human plasma gelsolin limits spontaneous EV shedding and subsequent
release of toxic material including anti-angiogenic and pro-inflamma-
tory factors [36]. Salomon et al. investigated the bioactivity of circulat-
ing placental exosomes and they found that the incubation of HUVEC
culture with these vesicles increase endothelial cell migration. Interest-
ingly, the bioactivity of exosomes was the greatest in the first trimester
and toned down in the course of pregnancy [14]. These results may in-
dicate that exosomes of trophoblast origin may facilitate the maternal
vascular adaptation to pregnancy.
Hsa-miR-210 is consistently overexpressed in the placenta and circu-
lation of women with PE [23]. Moreover, several groups have placen-
tal cell lines exposed to hypoxia, including cytotrophoblast, BeWo, and
JEG-3 [37–39]. However, hsa-miR-210 expression has not been assessed
in EVs, which could shed more light on the mechanism of the disease.
In our previous study, we created an interaction network by inte-
grating miRNA and mRNA expression profiles in normotensive and PE
placenta samples. In the group of upregulated miRNAs, we identified
miR-210 as a key regulator due to it targeted the most genes in the net-
work [40].
It is possible that EVs and miRNAs have opposing effects depend-
ing on different circumstances. For instance, tumor-derived exosomes
increase angiogenesis [41], while in PE, circulating exosomes of tro-
phoblast origin may lead to endothelial dysfunction [42]. mir-210 itself
is well-studied in cancer and bears tumor suppressor and oncogene func-
tions at the same time [43].
More than sixty genes have been experimentally validated as targets
of miR-210 up to now [44], and several others were predicted to be reg-
ulated by this miRNA [45]. These genes play important roles in various
cell processes such as apoptosis, proliferation, and metabolism.
Luo et al. established that upregulated potassium channel modu-
lator factor 1 (KCMF1), which is a validated target of miR-210 and
known to be underexpressed in PE, set back inhibition of trophoblast
invasion [46]. Upregulation of miR-210 may lead to placental mito-
chondria dysfunction and oxidative stress by causing repression of mi-
tochondria-associated iron-sulfur scaffold homologue (ISCU) [47]. Lee
et al. demonstrated that ISCU is a direct target of miR-210, exhibiting
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decreased levels in PE [38]. Ishibashi et al. found that miR-210 reg-
ulates 17-beta-hydroxysteroid dehydrogenase (HSD17B1), the enzyme
which is responsible for the production of estrone into 17β-estradiol.
Lower level of circulating HSD17B1 precedes the onset of PE, therefore
it is a potential prognostic factor for PE [39]. Ephrin-A3 (EFNA3) and
Homeobox-A9 (HOXA9) were then experimentally validated as the func-
tional targets of mir-210 [37]. EFNA3 is important for vascularization
and cell migration, especially in the cardiovascular system, and HOXA9
has been shown to be a key regulator of angiogenesis. Anton et al. found
that overexpressing miR-210 reduced trophoblast invasion and that el-
evated concentration in first-trimester serum samples was predictive of
the disease. They assumed that miR-210 suppresses trophoblast invasion
by targeting the MAPK and ERK signaling pathways. Both pathways are
known to participate in the regulation of trophoblast invasion [48]. Ko-
priva et al. demonstrated that Toll-like receptor 3 (TLR3) activation in-
duces placental miR-210 expression leading to the down-regulation of
the STAT6/Interleukin-4 pathway and this may contribute to the devel-
opment of PE [49].
All of the above-mentioned mechanisms are associated with the
main characteristics of PE, such as reduced trophoblast invasion and ox-
idative stress. Unfortunately, no research had been conducted related
to pregnancy, which would have elucidated the regulation of miR-210
in endothelial cells. We hypothesize that circulating exosomal miR-210
originates from the trophoblast layer, however, we cannot exclude other
sources for miR-210 in the maternal circulation. It is known that miR-
210 is expressed by endothelial cells [50] and endothelial dysfunction
is connected to PE. Therefore shedding of exosomal miR-210 from the
vasculature of pregnant women may be a source of miR-210 in the cir-
culation.
5. Conclusions
To the best of our knowledge, this was the first study which assessed
the exosomal miRNA concentration and expression in pregnancy-related
hypertension disorders, including chronic hypertension, gestational hy-
pertension, and preeclampsia. We conclude that the concentration of to-
tal-miRNA and exosomal hsa-miR-210 was significantly overexpressed
in the circulation of women affected by PE, and it was higher in severe
cases. Nevertheless, patient characteristics including BMI, birth weight,
and gestational age cannot be excluded as confounding factors in our
analysis. Based on our results it can be assumed that in PE, hsa-miR-210
is secreted via the exosomal pathway predominately, and it may con-
tribute to the multisystem nature of the disease.
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